| 产品描述: | Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue with anti-inflammatory activity. Anti-inflammatory agent 35 blocks mitogen-activated protein kinase (MAPK) signaling and p65 nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits yellow neutrophil infiltration and pro-inflammatory cytokine production. Anti-inflammatory agent 35 significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI) in vivo |
| 靶点: |
p38 MAPK;ERK;I-kappaBalpha;IL-6;p65;NF-κB;Immunology/Inflammationrelated |
| 体外研究: |
Anti-inflammatory agent 35 (化合物 5a27) (10 μM;30 分钟) 抑制 LPS (0.5 μg/mL;24 小时) 对促炎细胞因子 (IL-6、TNF-α) 产生的诱导作用,对小鼠原代巨噬细胞没有细胞毒性。Anti-inflammatory agent 35 抑制 IL-6、TNF-α 的产生,IC50 分别为 2.23 μM 和 2.40 μM。 Anti-inflammatory agent 35 (10 μM;30 分钟) 显着抑制 RAW 264.7 小鼠巨噬细胞中 LPS 诱导的激活。并且它显着抑制 p-p38 和 p-ERK,降低 IκB 水平,表明对 MAPK 和 NF-κB 信号的抑制。 |
| 体内研究: |
Anti-inflammatory agent 35 (化合物 5a27) (50 mg/kg;口服;单剂量,监测 0-25 分钟) 比姜黄素 (HY-N0005) 具有更好的生物利用度。 Anti-inflammatory agent 35 (10 mg/kg;腹腔注射;每天 1 次,共 1 周) 通过抑制小鼠模型中的炎症改善 LPS 诱导的 ALI Animal Model: ALI mouse model (C57BL/6 mice) Dosage: 10 mg/kg Administration: Intraperitoneal injection, once daily for 1 week; 30 min later every dose, followed by 5 mg/kg LPS, intratracheal injection Result: Significantly normalized the wet/dry ratio of lungs. |
| 参考文献: |
1. Qian J, et al. Design and synthesis novel di-carbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI). Eur J Med Chem. 2019 Apr 1;167:414-425. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.018 ml |
10.09 ml |
20.181 ml |
| 5 mM |
0.404 ml |
2.018 ml |
4.036 ml |
| 10 mM |
0.202 ml |
1.009 ml |
2.018 ml |
| 50 mM |
0.04 ml |
0.202 ml |
0.404 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |